Gelesis Holdings EBITDA 2021-2022 | GLS

Gelesis Holdings ebitda from 2021 to 2022. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Gelesis Holdings Annual EBITDA
(Millions of US $)
2021 $-21
2020 $-2
2019 $
Gelesis Holdings Quarterly EBITDA
(Millions of US $)
2022-03-31 $-41
2021-12-31 $0
2021-09-30 $-1
2021-06-30 $-0
2021-03-31 $-16
2020-12-31
2020-09-30 $-0
2020-06-30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.122B $0.011B
Gelesis is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Gelesis, formerly known as Capstar Special Purpose Acquisition Corp., is based in BOSTON.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $165.407B 10.06
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.180B 16.07
Biohaven Pharmaceutical Holding (BHVN) United States $10.170B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.223B 0.00
Arcus Biosciences (RCUS) United States $1.792B 45.42
Emergent Biosolutions (EBS) United States $1.625B 6.95
Myovant Sciences (MYOV) United Kingdom $1.313B 0.00
Zymeworks (ZYME) Canada $0.365B 0.00
Ambrx Biopharma (AMAM) United States $0.110B 0.00
Enzo Biochem (ENZ) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00